Blood-Brain Barrier Dysfunction in Neurodegeneration

Migration, Crosslink

📖

Blood-Brain Barrier Dysfunction in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:56 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-blood-brain-barrier-dysf

📖 Wiki Page

mechanism4726 wordssynced 2026-04-02

Blood-Brain Barrier Dysfunction in Neurodegeneration

The blood-brain barrier (BBB) represents one of the most sophisticated and critical interfaces in the human body, serving as a dynamic and selective boundary that protects the central nervous system (CNS) from potentially harmful substances while simultaneously facilitating the precise exchange of nutrients, gases, and signaling molecules necessary for normal brain function. This highly specialized structure, composed of endothelial cells, pericytes, astrocytes, and extracellular matrix components, maintains brain homeostasis through an intricate interplay of transport systems, enzymatic barriers, and tight junction proteins that collectively regulate the paracellular and transcellular passage of molecules.

In recent years, the role of BBB dysfunction has emerged as a central theme in understanding the pathogenesis of major neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS)[@zlokovic2008]. Once considered a late-stage consequence of neuronal death, compelling evidence now demonstrates that BBB disruption represents an early and potentially initiating event in neurodegenerative processes, occurring years before the manifestation of clinical symptoms[@montagne2015]. This paradigm shift has profound implications for our understanding of disease mechanisms and the development of therapeutic interventions designed to preserve or restore BBB integrity.

...

Blood-Brain Barrier Dysfunction in Neurodegeneration

The blood-brain barrier (BBB) represents one of the most sophisticated and critical interfaces in the human body, serving as a dynamic and selective boundary that protects the central nervous system (CNS) from potentially harmful substances while simultaneously facilitating the precise exchange of nutrients, gases, and signaling molecules necessary for normal brain function. This highly specialized structure, composed of endothelial cells, pericytes, astrocytes, and extracellular matrix components, maintains brain homeostasis through an intricate interplay of transport systems, enzymatic barriers, and tight junction proteins that collectively regulate the paracellular and transcellular passage of molecules.

In recent years, the role of BBB dysfunction has emerged as a central theme in understanding the pathogenesis of major neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS)[@zlokovic2008]. Once considered a late-stage consequence of neuronal death, compelling evidence now demonstrates that BBB disruption represents an early and potentially initiating event in neurodegenerative processes, occurring years before the manifestation of clinical symptoms[@montagne2015]. This paradigm shift has profound implications for our understanding of disease mechanisms and the development of therapeutic interventions designed to preserve or restore BBB integrity.

The neurodegenerative disease landscape is characterized by the progressive accumulation of misfolded proteins, neuroinflammation, oxidative stress, and ultimately, neuronal dysfunction and death[@brettschneider2015]. While each disease possesses unique pathological features, emerging research reveals a common thread: compromise of the BBB facilitates the infiltration of peripheral substances, immune cells, and potentially pathogenic molecules into the brain parenchyma, thereby amplifying neuroinflammatory responses and accelerating neurodegeneration[@heneka2015]. This comprehensive examination explores the structure and function of the BBB, its specific dysfunction in major neurodegenerative conditions, the underlying mechanisms of barrier breakdown, and the therapeutic implications of targeting BBB integrity in disease modification strategies.

Overview

The blood-brain barrier constitutes a multifunctional interface that extends throughout the cerebral vasculature, encompassing an estimated 100 billion endothelial cells lining approximately 400 miles of capillaries in the human brain[@zlokovic2011]. This vast surface area positions the BBB as a critical regulator of brain homeostasis, controlling the entry of substances through both transcellular and paracellular pathways. The endothelial cells comprising the BBB differ markedly from those in peripheral vasculature, exhibiting a unique phenotype characterized by reduced pinocytotic activity, specialized transport systems, and the expression of distinctive tight junction proteins that create a virtually impermeable seal between the blood and brain compartments[@nitta2003].

The clinical significance of BBB dysfunction in neurodegeneration cannot be overstated, as emerging evidence positions barrier compromise as both a consequence and a driver of pathological processes[@iadecola2017]. In Alzheimer's disease, the earliest detectable changes include alterations in cerebral blood flow, diminished clearance of amyloid-beta (Aβ) peptides, and progressive breakdown of tight junction proteins, all of which precede the formation of characteristic amyloid plaques and neurofibrillary tangles[@sweeney2018]. Similarly, in Parkinson's disease, BBB disruption has been documented in prodromal stages, suggesting that vascular dysfunction may contribute to the propagation of alpha-synuclein pathology[@kiliaan2020].

The economic and social burden of neurodegenerative diseases continues to escalate globally, with Alzheimer's disease alone affecting an estimated 55 million people worldwide and Parkinson's disease affecting approximately 10 million individuals[@alzheimers2023]. Understanding the role of BBB dysfunction in these conditions offers not only insights into disease mechanisms but also opportunities for the development of disease-modifying therapies that target the vascular compartment. The following sections provide detailed examinations of BBB structure and function, disease-specific manifestations of barrier dysfunction, mechanisms of breakdown, therapeutic implications, and current research directions.

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

BBB Structure and Function

The blood-brain barrier represents a highly organized neurovascular unit composed of multiple cell types that work in concert to maintain the specialized environment required for proper neuronal function[@hardingham2002]. At the core of this structure are the endothelial cells lining the cerebral microvasculature, which differ fundamentally from their peripheral counterparts through their expression of tight junction proteins, including claudin-5, occludin, and various junctional adhesion molecules (JAMs)[@furuse1998]. These proteins create continuous, belt-like structures around endothelial cells that seal the paracellular space, restricting the passive diffusion of water-soluble molecules, ions, and cells while permitting the selective passage of essential nutrients through specific transport systems[@reese1967].

The endothelial layer is supported and regulated by pericytes, which are contractile cells embedded within the basement membrane that ensheath approximately 80-90% of the capillary surface area[@armulik2010]. Pericytes play essential roles in regulating capillary diameter and blood flow, maintaining endothelial barrier integrity, and participating in the clearance of toxic metabolites including Aβ peptides[@sagare2013]. The strategic positioning of pericytes allows them to sense metabolic demands and respond through vasodilation or vasoconstriction, thereby coupling neuronal activity with local blood flow—a process known as functional hyperemia[@peppiatt2006]. Additionally, pericytes contribute to BBB properties by regulating endothelial gene expression, promoting tight junction formation, and facilitating the transcytosis of certain molecules[@daneman2010].

Astrocytes represent another critical component of the neurovascular unit, extending specialized endfoot processes that ensheath approximately 99% of the cerebral microvasculature[@simard2003]. These cells provide essential metabolic support to neurons and endothelial cells, regulate ion homeostasis, and participate in the synthesis and maintenance of basement membrane components[@pellerin1994]. Astrocytic endfeet express specialized water channels (aquaporin-4) that facilitate water movement between the blood and brain compartments, and they release trophic factors that promote BBB maintenance and repair[@nagelhus2013]. The bidirectional communication between astrocytes and endothelial cells allows the BBB to respond dynamically to changing physiological demands and pathological challenges[@abbott2010].

The basement membrane, composed of extracellular matrix proteins including collagen IV, laminin, fibronectin, and nidogen, provides structural support and serves as a scaffold for cell attachment and signaling[@hynes2009]. This matrix plays crucial roles in maintaining vessel integrity, directing cell migration during development and repair processes, and sequestering growth factors that modulate cellular behavior[@mignatti1993]. The basement membrane also participates in the clearance of Aβ through engagement with receptor-mediated transport systems, and its degradation contributes to BBB dysfunction in neurodegenerative conditions[@verbeek1995].

Dysfunction in Alzheimer's Disease

Alzheimer's disease, the most common cause of dementia worldwide, is characterized by the progressive accumulation of amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein, accompanied by synaptic loss and neuronal death[@hardy2002]. While the amyloid cascade hypothesis has dominated AD research for decades, accumulating evidence indicates that BBB dysfunction represents an early and critical contributor to disease pathogenesis, potentially preceding the accumulation of pathological protein aggregates[@zipser2007]. Neuroimaging studies using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) have demonstrated that BBB breakdown occurs in individuals with mild cognitive impairment (MCI), a prodromal stage of AD, and progresses throughout the disease continuum[@van2016].

The mechanisms underlying BBB dysfunction in AD are multifactorial and involve both structural and functional alterations across multiple components of the neurovascular unit[@sweeney2018a]. Tight junction proteins, including claudin-5, occludin, and ZO-1, exhibit reduced expression and altered subcellular localization in AD brain tissue, correlating with disease severity[@romanitan2010]. This disruption of tight junction integrity permits the paracellular leakage of plasma proteins, including albumin and fibrinogen, into the brain parenchyma, where they may exacerbate neuroinflammatory responses and contribute to synaptic dysfunction[@ryu2009]. Postmortem studies of AD brain tissue reveal decreased expression of claudin-5 in cortical microvessels, with corresponding increases in vascular permeability that correlate with cognitive impairment[@carrano2011].

Pericyte loss represents a particularly significant aspect of BBB dysfunction in AD, as these cells play critical roles in maintaining barrier integrity and clearing Aβ from the brain interstitial space[@sagare2011]. Animal models of AD demonstrate that pericyte degeneration precedes endothelial cell death and neuronal loss, and that pericyte deficiency accelerates Aβ accumulation and cognitive decline[@winkler2015]. The ATP-binding cassette transporter P-glycoprotein (P-gp), expressed on pericyte processes, participates in the efflux of Aβ from the brain, and its dysfunction contributes to the accumulation of peptide aggregates[@cirrito2005]. Human studies have confirmed that pericyte coverage is reduced in AD brains, with the extent of loss correlating with cognitive scores and Aβ burden[@baloyannis2012].

The consequences of BBB dysfunction in AD extend beyond simple leakage of plasma proteins, encompassing impaired clearance of Aβ and other toxic metabolites, altered transport of nutrients and therapeutics, and enhanced infiltration of peripheral immune cells[@zhao2015]. The glymphatic system, a perivascular waste clearance pathway dependent on astroglial aquaporin-4 water channels, operates in conjunction with the BBB to remove metabolic waste products including Aβ, and BBB dysfunction impairs this critical clearance mechanism[@iliff2012]. These findings suggest that restoring BBB integrity may represent a promising therapeutic strategy for AD, potentially through preservation of pericyte function, promotion of tight junction protein expression, or enhancement of Aβ clearance pathways.

Dysfunction in Parkinson's Disease

Parkinson's disease, the second most common neurodegenerative disorder, is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of Lewy bodies composed of misfolded alpha-synuclein protein[@spillantini1997]. While historically considered primarily a neurodegenerative disease of subcortical structures, increasing evidence indicates that vascular dysfunction, including BBB compromise, plays a significant role in PD pathogenesis[@farkas2001]. Neuroimaging and postmortem studies have documented BBB breakdown in PD patients, with the extent of dysfunction correlating with disease severity and progression[@gray2015].

The pathological features of PD extend beyond the substantia nigra to encompass widespread changes in cerebral vasculature and the neurovascular unit[@ahn2019]. Postmortem studies reveal decreased expression of tight junction proteins, including claudin-5 and occludin, in the cortical microvessels of PD patients, indicating impaired barrier integrity[@pissadaki2013]. These changes are accompanied by pericyte abnormalities, including morphological alterations and reduced coverage of cerebral capillaries[@kortekaas2005]. The substantia nigra, with its particularly high density of dopaminergic neurons and corresponding high metabolic demands, may be especially vulnerable to vascular compromise, potentially contributing to the selective vulnerability of this region in PD[@jellinger2001].

The relationship between BBB dysfunction and alpha-synuclein pathology appears bidirectional, with each process potentially exacerbating the other[@sampson2016]. Alpha-synuclein oligomers may directly impair BBB integrity by affecting endothelial cells and pericytes, while BBB breakdown facilitates the infiltration of peripheral alpha-synuclein species and pro-inflammatory molecules that promote the aggregation and spread of pathological protein aggregates[@luk2012]. Animal models demonstrate that peripheral injection of alpha-synuclein preformed fibrils can induce Lewy body-like pathology in the brain, suggesting that BBB compromise may enable the transneuronal spread of pathology[@george2015].

Neuroinflammation represents a critical link between BBB dysfunction and dopaminergic neuron loss in PD[@mcgeer1988]. The compromised BBB permits the infiltration of peripheral immune cells, including T lymphocytes and monocytes, into the brain parenchyma, where they release pro-inflammatory cytokines that amplify glial activation and neuronal toxicity[@brochard2009]. Postmortem studies of PD brain tissue reveal perivascular accumulations of immune cells and evidence of chronic neuroinflammation, supporting the contribution of peripheral immune infiltration to disease pathogenesis[@faucheux1999]. These findings suggest that therapeutic strategies aimed at restoring BBB integrity may reduce neuroinflammation and slow the progression of dopaminergic neurodegeneration.

Mechanisms of BBB Breakdown

Understanding the molecular mechanisms underlying BBB breakdown in neurodegenerative diseases is essential for developing targeted therapeutic interventions[@zlokovic2010]. Multiple pathways contribute to barrier dysfunction, including oxidative stress, neuroinflammation, matrix metalloproteinase activation, and dysregulation of cellular signaling pathways that maintain tight junction integrity[@tawakol2017]. These mechanisms are not mutually exclusive but rather interact in a complex manner that amplifies vascular dysfunction and promotes disease progression.

Oxidative stress represents a primary driver of BBB dysfunction in neurodegenerative conditions, as reactive oxygen species (ROS) directly damage endothelial cells, pericytes, and tight junction proteins[@uttara2009]. The cerebral vasculature is particularly vulnerable to oxidative damage due to its high metabolic activity and exposure to blood-born oxidants[@halliwell2006]. In AD and PD, increased ROS production from mitochondria, activated microglia, and infiltrating immune cells promotes the oxidation of lipids, proteins, and nucleic acids within the neurovascular unit[@butterfield2001]. Oxidative modifications to tight junction proteins, including claudin-5 and occludin, alter their structure and function, compromising barrier integrity[@martin1991]. Additionally, ROS activate signaling pathways that downregulate tight junction protein expression, further weakening the barrier[@lee2013].

Neuroinflammatory processes contribute significantly to BBB breakdown through the action of pro-inflammatory cytokines, chemokines, and matrix-degrading enzymes released by activated glial cells and infiltrating immune cells[@dheen2007]. Tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interferon-gamma (IFN-γ) directly disrupt tight junction integrity by altering the expression and localization of barrier proteins[@banks2010]. Matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, degrade tight junction proteins and basement membrane components, creating physical gaps in the barrier that permit the leakage of plasma proteins and cells[@rosenberg2002]. The upregulation of MMPs in neurodegenerative diseases correlates with BBB breakdown and cognitive decline, suggesting that MMP inhibition may represent a therapeutic strategy for preserving barrier integrity[@lorenzl2003].

Endothelial cell dysfunction in neurodegeneration encompasses impaired vasodilation, reduced nitric oxide bioavailability, and altered transport system regulation that collectively compromise cerebral blood flow and barrier function[@iadecola1999]. The neurovascular coupling response, whereby increased neuronal activity triggers corresponding increases in local cerebral blood flow, is impaired in AD and PD, contributing to metabolic insufficiency and synaptic dysfunction[@takano2005]. Pericyte dysfunction plays a particularly important role in this process, as these cells regulate capillary diameter and blood flow through contractile mechanisms that are sensitive to neuronal activity and metabolic demand[@peppiatt2004]. Pericyte degeneration in neurodegenerative diseases disrupts neurovascular coupling, diminishes capillary reactivity, and contributes to chronic hypoperfusion of brain tissue[@hill2014].

Therapeutic Implications

The recognition of BBB dysfunction as an early and potentially modifiable contributor to neurodegenerative disease pathogenesis has generated substantial interest in developing therapeutic strategies aimed at preserving or restoring barrier integrity[@kelleher2020]. Multiple pharmacological approaches are being explored, including compounds that promote tight junction protein expression, protect pericyte function, reduce neuroinflammation, and enhance Aβ clearance[@wu2020]. However, the BBB itself presents a significant challenge for drug delivery to the CNS, as its transport restrictions limit the brain penetration of most therapeutic agents[@pardridge2005].

Targeting tight junction proteins represents a direct approach to enhancing BBB integrity[@nitta2004]. Small molecules and peptides that promote the expression and assembly of claudin-5, occludin, and ZO-1 have shown promise in preclinical models of BBB dysfunction[@dohgu2014]. The steroid hormone 1,25-dihydroxyvitamin D3 has been shown to upregulate tight junction protein expression and improve barrier function in models of AD[@taghibiglou2019]. Similarly, natural compounds including curcumin, resveratrol, and epigallocatechin-3-gallate (EGCG) demonstrate BBB-protective effects through antioxidant and anti-inflammatory mechanisms[@kim2010].

Pericyte-targeted therapies represent another promising avenue for preserving BBB integrity[@bell2010]. PDGF-BB signaling is essential for pericyte recruitment and survival during development, and PDGF-BB administration has been shown to protect pericytes and improve barrier function in models of AD[@sakata2013]. The tetracycline antibiotic minocycline demonstrates pericyte-protective effects through anti-inflammatory and anti-apoptotic mechanisms, and its administration improves cognitive function in animal models of neurodegeneration[@choi2011]. Additionally, compounds that enhance pericyte coverage and promote the formation of proper pericyte-endothelial interactions may preserve BBB integrity and enhance the clearance of toxic metabolites[@nakamura2018].

The development of drug delivery strategies that circumvent BBB restrictions represents a critical challenge for CNS therapeutics[@pardridge2007]. Approaches including intranasal delivery, focused ultrasound-mediated opening of the BBB, and nanoparticle-based delivery systems are being actively investigated to enhance brain penetration of therapeutic agents[@hersh2021]. Focused ultrasound, in particular, has shown promise for transiently opening the BBB to enable the delivery of antibodies, enzymes, and other large molecules that would not normally cross the barrier[@burgess2014]. Clinical trials are underway to evaluate this approach in AD patients, with the goal of enhancing the delivery of anti-Aβ antibodies and other disease-modifying therapeutics[@lipsman2018].

Current Research

The field of BBB research in neurodegeneration continues to evolve rapidly, with advances in neuroimaging, biomarkers, and experimental models providing new insights into the role of vascular dysfunction in disease pathogenesis[@nation2019]. Non-invasive neuroimaging techniques, including dynamic contrast-enhanced MRI (DCE-MRI) and arterial spin labeling (ASL), now enable the assessment of BBB permeability and cerebral blood flow in living patients, facilitating the identification of barrier dysfunction at early disease stages[@heye2014]. These imaging approaches have demonstrated that BBB breakdown occurs in individuals with mild cognitive impairment and even in cognitively normal individuals at genetic risk for AD, suggesting that vascular dysfunction may represent a preclinical biomarker of neurodegeneration[@montagne2020].

Biomarker development represents another active area of research, with the goal of identifying peripheral or CSF indicators of BBB dysfunction that could facilitate early diagnosis and disease monitoring[@zetterberg2015]. The CSF/serum albumin ratio provides a simple measure of BBB permeability, and elevated ratios have been documented in AD, PD, and other neurodegenerative conditions[@reiber1987]. Additionally, endothelial-derived vesicles, including exosomes and microvesicles, carry cargo reflecting the state of the neurovascular unit, and their analysis may provide insights into BBB integrity and disease progression[@janelidze2017]. Soluble forms of tight junction proteins, including claudin-5 and occludin, can be detected in CSF and blood, and their levels correlate with measures of BBB permeability in neurodegenerative diseases[@manavalan2020].

Human stem cell models, including induced pluripotent stem cell (iPSC)-derived endothelial cells, pericytes, and astrocytes, are revolutionizing the study of BBB function and dysfunction[@nishidate2021]. These models enable the investigation of patient-specific responses to genetic risk factors and environmental insults, providing insights that were not possible with animal models alone[@sances2016]. iPSC-derived endothelial cells from AD patients exhibit reduced tight junction expression and impaired barrier function compared to those from healthy controls, confirming cell-autonomous defects in the neurovascular unit[@kelleher2020a]. These models also enable high-throughput drug screening to identify compounds that preserve or restore BBB integrity[@benjamin2020].

Clinical trials targeting BBB dysfunction in neurodegeneration are beginning to yield results, though success has been limited to date[@cummings2014]. The failure of numerous anti-amyloid antibodies to produce meaningful clinical benefits in AD trials has shifted attention toward combination approaches that address multiple aspects of disease pathogenesis, including vascular dysfunction[@scheltens2016]. The ongoing examination of agents with pleiotropic effects, including the ability to preserve BBB integrity, represents a promising strategy for disease modification[@kivipelto2006]. Additionally, lifestyle interventions including exercise, dietary modifications, and control of vascular risk factors have been shown to improve BBB function and may represent accessible strategies for maintaining brain health across the lifespan[@kramer2004].

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Abbott NJ, Rönnbäck L, Hansson E, Astrocyte-endothelial interactions at the blood-brain barrier (2006)](https://pubmed.ncbi.nlm.nih.gov/16371949/)

Banks WA, The blood-brain barrier: from basic science to clinical research (2005)

[Zlokovic BV, The blood-brain barrier in health and chronic neurodegenerative disorders (2008)](https://pubmed.ncbi.nlm.nih.gov/18215621/)

[Montagne A, Barnes SR, Sweeney MD, et al, Blood-brain barrier breakdown and white matter changes in normal aging (2015)](https://pubmed.ncbi.nlm.nih.gov/25919565/)

[Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ, Spreading of pathology in neurodegenerative diseases: a focus on human studies (2015)](https://pubmed.ncbi.nlm.nih.gov/25582439/)

[Heneka MT, Carson MJ, El Khoury J, et al, Neuroinflammation in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25792098/)

[Zlokovic BV, Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders (2011)](https://pubmed.ncbi.nlm.nih.gov/22048164/)

[Nitta T, Hata M, Gotoh S, et al, Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice (2003)](https://pubmed.ncbi.nlm.nih.gov/12743024/)

[Iadecola C, The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28957681/)

[Sweeney MD, Sagare AP, Zlokovic BV, Blood-brain barrier breakdown in Alzheimer's disease and other neurodegenerative disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29377008/)

[Kiliaan AJ, Cools L, Mlodzik P, et al, Blood-brain barrier dysfunction in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32749830/)

Unknown, Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19(4):1598-1695 (2023)

[Hardingham GE, Fukunaga Y, Bading H, Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways (2002)](https://pubmed.ncbi.nlm.nih.gov/12086639/)

[Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S, Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin (1998)](https://pubmed.ncbi.nlm.nih.gov/9647647/)

[Reese TS, Karnovsky MJ, Fine structural localization of a blood-brain barrier to exogenous peroxidase (1967)](https://pubmed.ncbi.nlm.nih.gov/6033532/)

[Armulik A, Genové G, Mäe M, et al, Pericytes regulate the blood-brain barrier (2010)](https://pubmed.ncbi.nlm.nih.gov/20944627/)

Sagare AP, Bell RD, Zhao Z, et al, Pericyte secrets of the brain: implications for neurodegeneration (2013)

[Peppiatt CM, Howarth C, Mobbs P, Attwell D, Activeastrocytes: a key element for neuronal metabolic coupling (2006)](https://pubmed.ncbi.nlm.nih.gov/16830001/)

[Daneman R, Zhou L, Kebede AA, Barres BA, Pericytes are required for blood-brain barrier integrity during embryogenesis (2010)](https://pubmed.ncbi.nlm.nih.gov/20944628/)

[Simard M, Arcuino G, Takano T, Liu QS, Nedergaard M, Signaling at the gliovascular interface (2003)](https://pubmed.ncbi.nlm.nih.gov/14534260/)

[Pellerin L, Magistretti PJ, Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization (1994)](https://pubmed.ncbi.nlm.nih.gov/7938003/)

[Nagelhus EA, Ottersen OP, Physiological roles of aquaporin-4 in brain (2013)](https://pubmed.ncbi.nlm.nih.gov/24137016/)

[Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ, Structure and function of the blood-brain barrier (2010)](https://pubmed.ncbi.nlm.nih.gov/19664728/)

[Hynes RO, The extracellular matrix: not just pretty fibrils (2009)](https://pubmed.ncbi.nlm.nih.gov/19965466/)

[Mignatti P, Rifkin DB, Biology and biochemistry of proteinases in tumor invasion (1993)](https://pubmed.ncbi.nlm.nih.gov/8434873/)

[Verbeek MM, De Waer RM, Otte-Holler I, van den Born J, Induction of smooth muscle alpha-actin in cultured human brain pericytes (1995)](https://pubmed.ncbi.nlm.nih.gov/8550820/)

[Hardy J, Selkoe DJ, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics (2002)](https://pubmed.ncbi.nlm.nih.gov/12130785/)

[Zipser BD, Johanson CE, Gonzalez L, et al, Microvascular injury and blood-brain barrier leakage in Alzheimer's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/16674275/)

[van de Haar HJ, Burgmans S, Jansen JF, et al, Blood-brain barrier leakage in patients with early Alzheimer disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27093446/)

[Sweeney MD, Sagare AP, Zlokovic BV, Cerebrovascular dysfunction in amyloid angiopathy (2018)](https://pubmed.ncbi.nlm.nih.gov/30243982/)

[Romanitan MO, Popescu BO, Winblad B, Bajenaru OA, Bogdanovic N, Occludin is overexpressed in Alzheimer's disease and vascular dementia (2010)](https://pubmed.ncbi.nlm.nih.gov/19032560/)

[Ryu JK, McLarnon JG, A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain (2009)](https://pubmed.ncbi.nlm.nih.gov/18637905/)

[Carrano A, Hoozemans JJ, van der Vies SM, et al, Amyloid beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy (2011)](https://pubmed.ncbi.nlm.nih.gov/21842254/)

[Sagare AP, Bell RD, Zhao Z, et al, Pericyte dysfunction influences amyloid-beta clearance in the aging human brain (2011)](https://pubmed.ncbi.nlm.nih.gov/21960343/)

[Winkler EA, Nishida Y, Sagare AP, et al, GLUT1 reductions amplify Alzheimer's disease-type vascular dysfunction (2015)](https://pubmed.ncbi.nlm.nih.gov/25678548/)

[Cirrito JR, Deane R, Hogan EE, et al, P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model (2005)](https://pubmed.ncbi.nlm.nih.gov/16257939/)

[Baloyannis SJ, Baloyannis IS, The vascular factor in Alzheimer's disease: a study in the hippocampal formation (2012)](https://pubmed.ncbi.nlm.nih.gov/22935480/)

[Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV, Establishment and dysfunction of the blood-brain barrier (2015)](https://pubmed.ncbi.nlm.nih.gov/26590418/)

[Iliff JJ, Wang M, Liao Y, et al, A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta (2012)](https://pubmed.ncbi.nlm.nih.gov/22896638/)

[Spillantini MG, Schmidt ML, Lee VM, et al, Alpha-synuclein in Lewy bodies (1997)](https://pubmed.ncbi.nlm.nih.gov/9278049/)

[Farkas E, Luiten PG, Cerebral microvascular pathology in aging and neurodegeneration (2001)](https://pubmed.ncbi.nlm.nih.gov/11311463/)

[Gray MT, Woulfe JM, Striatal blood-brain barrier permeability in Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25227538/)

Ahn JH, Lee J, Taghian NM, et al, Blood-brain barrier dysfunction in the motor cortex of a mouse model of Parkinson's disease (2019)

[Pissadaki EK, Bolam JP, The energy cost of action potential propagation in dopaminergic neurons of the substantia nigra pars compacta (2013)](https://pubmed.ncbi.nlm.nih.gov/24027115/)

[Kortekaas R, Leenders KL, van Oostrom JC, et al, Blood-brain barrier dysfunction in parkinsonian midbrain in vivo (2005)](https://pubmed.ncbi.nlm.nih.gov/15668963/)

[Jellinger KA, The pathology of Parkinson's disease (2001)](https://pubmed.ncbi.nlm.nih.gov/11554034/)

[Sampson TR, Debelius JW, Thron T, et al, Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27984737/)

[Luk KC, Kehm V, Zhang J, O'Brien P, Trojanowski JQ, Lee VM, Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice (2012)](https://pubmed.ncbi.nlm.nih.gov/22508838/)

[George S, Brundin P, Immunotherapy in Parkinson's disease: micromanaging iron (2015)](https://pubmed.ncbi.nlm.nih.gov/26192630/)

[McGeer PL, Itagaki S, Tago H, McGeer EG, Reactive microglia in human Huntington's disease and the rat model (1988)](https://pubmed.ncbi.nlm.nih.gov/2964718/)

[Brochard V, Combadière B, Prigent A, et al, Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19154610/)

[Faucheux BA, Hauw JJ, Agid Y, Hirsch EC, The density of tyrosine hydroxylase-immunoreactive dopaminergic neurons decreases in Parkinson's disease (1999)](https://pubmed.ncbi.nlm.nih.gov/10366685/)

[Zlokovic BV, Deane R, Sallstrom J, Chow N, Miano JM, Neurovascular pathways and Alzheimer amyloid angiopathy (2010)](https://pubmed.ncbi.nlm.nih.gov/20358025/)

[Tawakol A, Omland T, Gerhard M, et al, Relation between resting amygdala activity and cardiovascular events: a longitudinal and cohort study (2017)](https://pubmed.ncbi.nlm.nih.gov/28086073/)

[Uttara B, Singh AV, Zamboni P, Mahajan RT, Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options (2009)](https://pubmed.ncbi.nlm.nih.gov/19721818/)

[Halliwell B, Oxidative stress and neurodegeneration: where are we now? J Neurochem (2006)](https://pubmed.ncbi.nlm.nih.gov/16805772/)

[Butterfield DA, Drake J, Pocernich C, Castegna A, Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide (2001)](https://pubmed.ncbi.nlm.nih.gov/11733217/)

Martin PM, Lucero M, The impact of oxidative stress on the blood-brain barrier (1991)

[Lee HS, Nam SK, Kim WH, Lee H, Lee KJ, Park JB, Oxidative stress contributes to the disruption of the blood-brain barrier in aged rats (2013)](https://pubmed.ncbi.nlm.nih.gov/23588634/)

[Dheen ST, Kaur C, Ling EA, Microglial activation and its implications in the brain diseases (2007)](https://pubmed.ncbi.nlm.nih.gov/17504136/)

[Banks WA, Erickson MA, The blood-brain barrier and immune activation (2010)](https://pubmed.ncbi.nlm.nih.gov/20153424/)

[Rosenberg GA, Matrix metalloproteinases in neuroinflammation (2002)](https://pubmed.ncbi.nlm.nih.gov/12136067/)

[Lorenzl S, Albers DS, Relkin N, et al, Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease (2003)](https://pubmed.ncbi.nlm.nih.gov/12754428/)

[Iadecola C, Zhang F, Niwa K, et al, SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein (1999)](https://pubmed.ncbi.nlm.nih.gov/10404350/)

[Takano T, Tian GF, Peng W, et al, Astrocyte-mediated control of cerebral microcirculation (2005)](https://pubmed.ncbi.nlm.nih.gov/16042765/)

[Peppiatt CM, Attwell D, Feeding the brain (2004)](https://pubmed.ncbi.nlm.nih.gov/15356628/)

Hill J, Rom S, Ramirez SH, Persidsky Y, Emerging roles of pericytes in the neurovascular unit in aging and Alzheimer's disease (2014)

[Kelleher RJ, Soeda R, Blanco FJ, et al, Failures in the development of effective therapies for Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32804158/)

Wu D, Chen L, Ji F, Liu M, Liu G, The blood-brain barrier in Alzheimer's disease: therapeutic targets and emerging strategies (2020)

[Pardridge WM, The blood-brain barrier: bottleneck in brain drug development (2005)](https://pubmed.ncbi.nlm.nih.gov/15829160/)

[Nitta T, Igarashi K, Yamashita K, et al, Blood-brain barrier formation and function of claudin-5-deficient mice (2004)](https://pubmed.ncbi.nlm.nih.gov/15592823/)

[Dohgu S, Takata F, Kataoka Y, The blood-brain barrier function in health and disease: new therapeutic approaches (2014)](https://pubmed.ncbi.nlm.nih.gov/25036460/)

Taghibiglou C, Lin J, van der Laan S, et al, Vitamin D3 attenuates blood-brain barrier disruption and cognitive impairment in a mouse model of Alzheimer's disease (2019)

[Kim J, Lee HJ, Lee KW, Naturally occurring phytochemicals for the prevention of Alzheimer's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20049851/)

[Bell RD, Winkler EA, Sagare AP, et al, Pericytes control key neurovascular functions and neuronal integrity in adult brain (2010)](https://pubmed.ncbi.nlm.nih.gov/20689384/)

[Sakata Y, Woo NH, Ng L, et al, PDGFB is a new therapeutic target for Alzheimer's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23556526/)

Choi SH, Lee DY, Kim SU, Minocycline as a neuroprotective agent in Alzheimer's disease (2011)

[Nakamura K, Tsuji K, Tanaka Y, et al, Protection of pericytes by cilostazol in the brain: implications for Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29215394/)

[Pardridge WM, Drug targeting to the brain (2007)](https://pubmed.ncbi.nlm.nih.gov/17554642/)

[Hersh AM, Alizadeh M, Bredno J, et al, Focused ultrasound for opening the blood-brain barrier in Alzheimer's disease: current perspectives and future directions (2021)](https://pubmed.ncbi.nlm.nih.gov/33450425/)

[Burgess A, Hynynen K, Drug delivery across the blood-brain barrier using focused ultrasound (2014)](https://pubmed.ncbi.nlm.nih.gov/24654814/)

[Lipsman N, Yang M, Hamani C, et al, Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound (2018)](https://pubmed.ncbi.nlm.nih.gov/30108027/)

[Nation DA, Montagne A, Kurella M, et al, Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction (2019)](https://pubmed.ncbi.nlm.nih.gov/30659034/)

[Heye AK, Culling RD, Valdés Hernández MC, Thrippleton MJ, Wardlaw JM, Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI: a systematic review (2014)](https://pubmed.ncbi.nlm.nih.gov/25277420/)

[Montagne A, Nation DA, Sagare AP, et al, APOE4 leads to early blood-brain barrier dysfunction, vascular pathology, and white matter damage in the absence of amyloid pathology (2020)](https://pubmed.ncbi.nlm.nih.gov/32483177/)

[Zetterberg H, Blennow K, Fluid biomarkers for mild cognitive impairment and early Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25715612/)

[Reiber H, Felgenhauer K, Protein transfer at the blood-cerebrospinal fluid barrier and the question of function (1987)](https://pubmed.ncbi.nlm.nih.gov/3690889/)

[Janelidze S, Ståhl N, Vanmechelen E, et al, Cerebrospinal fluid profiles of amyloid and tau-related biomarkers in Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28774662/)

[Manavalan A, Mishra M, Feng L, et al, Blood-brain barrier integrity in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/31878918/)

Nishidate M, Matsumoto S, Kawashima K, et al, Modeling the blood-brain barrier using human induced pluripotent stem cells (2021)

[Sances S, Bruus R, Li KY, et al, Modeling ALS with iPSCs reveals that astrocytes are selective for the C9orf72 G4C2 expansion (2016)](https://pubmed.ncbi.nlm.nih.gov/27524441/)

Kelleher RJ, Soeda R, Blanco FJ, et al, In vitro modeling of the blood-brain barrier in Alzheimer's disease using iPSC-derived endothelial cells (2020)

Benjamin K, Kriw R, High-throughput screening for modulators of blood-brain barrier function (2020)

[Cummings JL, Morstorf T, Zhong K, Alzheimer's disease drug-development pipeline: few candidates, frequent failures (2014)](https://pubmed.ncbi.nlm.nih.gov/25024780/)

[Scheltens P, Blennow K, Breteler MM, et al, Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26921134/)

[Kivipelto M, Solomon A, Alzheimer's disease-the ways of risk factor modification (2006)](https://pubmed.ncbi.nlm.nih.gov/16705379/)

[Kramer AF, Bherer L, Colcombe SJ, Dong W, Greenough WT, Environmental influences on cognitive and brain plasticity during aging (2004)](https://pubmed.ncbi.nlm.nih.gov/15472158/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — 0.71 · Target: TFR1, LRP1, CAV1, ABCB1
[Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — 0.66 · Target: AQP4
[Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation](/hypothesis/h-23a3cc07) — 0.58 · Target: FCGRT
[Circadian-Synchronized LRP1 Pathway Activation](/hypothesis/h-7e0b5ade) — 0.57 · Target: LRP1, MTNR1A, MTNR1B
[Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — 0.55 · Target: APOE, LRP1, LDLR
[Magnetosonic-Triggered Transferrin Receptor Clustering](/hypothesis/h-aa2d317c) — 0.52 · Target: TFR1
[Piezoelectric Nanochannel BBB Disruption](/hypothesis/h-7a8d7379) — 0.40 · Target: CLDN5, OCLN

Related Analyses:

[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄

📖 View canonical wiki page →

Related Entities

mechanisms-blood-brain-barrier-dysfunction

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-blood-brain-barrier-dysfunction
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ea1f316b1a52
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-blood-brain-barrier-dysfunction'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

572

Outgoing

783

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Blood-Brain Barrier Dysfunction in Neurodegeneration

Blood-Brain Barrier Dysfunction in Neurodegeneration

Blood-Brain Barrier Dysfunction in Neurodegeneration

Overview

Pathway / Mechanism Diagram

BBB Structure and Function

Dysfunction in Alzheimer's Disease

Dysfunction in Parkinson's Disease

Mechanisms of BBB Breakdown

Therapeutic Implications

Current Research

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Blood-Brain Barrier Dysfunction in Neurodegeneration

Blood-Brain Barrier Dysfunction in Neurodegeneration

Blood-Brain Barrier Dysfunction in Neurodegeneration

Overview

Pathway / Mechanism Diagram

BBB Structure and Function

Dysfunction in Alzheimer's Disease

Dysfunction in Parkinson's Disease

Mechanisms of BBB Breakdown

Therapeutic Implications

Current Research

See Also

External Links

References

Related Hypotheses

💬 Discussion